🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prodromal Alpha-Synuclein Screening in Parkinson's Disease Study

Recruitingn/aAges 50 Years - 99 YearsAllUniversity Hospital Schleswig-Holstein
NCT04724941 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The PASS-PD study is set out to screen individuals from the general population with an increased risk for the development of Parkinson's Disease (PD) and to investigate this highly enriched cohort longitudinally for five year. A special focus is placed on implementation of ethical standards for early risk disclosure in PD.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age between 50 and 99 Exclusion Criteria: * Presence of clinical PD at the time of study inclusion * Other significant neurologic diseases affecting the central nervous system (e.g. Multiple sclerosis) * other significant diseases e.g. orthopaedic diseases affecting quantitative motor assessment * in case of participation in the lumbal puncture substudy: contraindications for the performance of lumbal puncture (bleeding tendency, intake of anticoagulants)
💊

What it tests

  • No intervention
📍

Where

1 site
Department for Neurology, University of Kiel
Kiel, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy